pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC
Cartesian Therapeutics
Cartesian Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 7495 New Horizon Way, Frederick, Maryland 21703, US
- Founded
- 2016
- Employees
- 89
- Programs
- 12
- Drugs
- 4
- Patents
- 4
Cartesian Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Cartesian Therapeutics.
Cartesian Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Descartes 08
Cartesian Therapeutics
Myeloma Multiple
1 trial -
Descartes-08
Cartesian Therapeutics
Antisynthetase Syndrome
1 trial -
Descartes-08
Cartesian Therapeutics
Childhood-onset Systemic Lupus Erythematous
1 trial -
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
1 trial -
Descartes-08
Cartesian Therapeutics
Systemic Lupus Erythematosus (SLE)
1 trial -
Descartes-11
Cartesian Therapeutics
Multiple Myeloma
2 trials
Frequently asked questions
How many clinical projects does Cartesian Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.